Drug screening of food and drug administration-approved compounds against Babesia bovis in vitro.

Drug screening of food and drug administration-approved compounds against Babesia bovis in vitro. Exp Parasitol. 2020 Jan 08;:107831 Authors: Li Y, Liu M, Rizk MA, Moumouni PFA, Lee SH, Galon EM, Guo H, Gao Y, Li J, Beshbishy AM, Nugraha AB, Ji S, Tumwebaze MA, Benedicto B, Yokoyama N, Igarashi I, Xuan X Abstract Babesia (B.) bovis is one of the main etiological agents of bovine babesiosis, causes serious economic losses to the cattle industry. Control of bovine babesiosis has been hindered by the limited treatment selection for B. bovis, thus, new options are urgently needed. We explored the drug library and unbiasedly screened 640 food and drug administration (FDA) approved drug compounds for their inhibitory activities against B. bovis in vitro. The initial screening identified 13 potentially effective compounds. Four potent compounds, namely mycophenolic acid (MPA), pentamidine (PTD), doxorubicin hydrochloride (DBH) and vorinostat (SAHA) exhibited the lowest IC50 and then selected for further evaluation of their in vitro efficacies using viability, combination inhibitory and cytotoxicity assays. The half-maximal inhibitory concentration (IC50) values of MPA, PTD, DBH, SAHA were 11.38 ± 1.66, 13.12 ± 4.29, 1.79 ± 0.15 and 45.18 ± 7.37 μM, respectively. Of note, DBH exhibited IC50 lower than that calculated for the commonly used antibabesial drug, diminazene aceturate (DA). The viability result revealed the a...
Source: Experimental Parasitology - Category: Parasitology Authors: Tags: Exp Parasitol Source Type: research